These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 28294980)

  • 41. Differential expression profiling and functional analysis of microRNAs through stage I-III papillary thyroid carcinoma.
    Zhang J; Liu Y; Liu Z; Wang XM; Yin DT; Zheng LL; Zhang DY; Lu XB
    Int J Med Sci; 2013; 10(5):585-92. PubMed ID: 23533107
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroRNA Profiling in Papillary Thyroid Cancer.
    Armos R; Bojtor B; Papp M; Illyes I; Lengyel B; Kiss A; Szili B; Tobias B; Balla B; Piko H; Illes A; Putz Z; Kiss A; Toth E; Takacs I; Kosa JP; Lakatos P
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Family of microRNA-146 Regulates RARβ in Papillary Thyroid Carcinoma.
    Czajka AA; Wójcicka A; Kubiak A; Kotlarek M; Bakuła-Zalewska E; Koperski Ł; Wiechno W; Jażdżewski K
    PLoS One; 2016; 11(3):e0151968. PubMed ID: 27011326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncogenic alterations in papillary thyroid cancers of young patients.
    Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
    Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma.
    Al-Abdallah A; Jahanbani I; Mehdawi H; Ali RH; Al-Brahim N; Mojiminiyi O; Junaid TA
    Exp Mol Pathol; 2020 Apr; 113():104379. PubMed ID: 31935378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MicroRNA expression profiles in the management of papillary thyroid cancer.
    Lee JC; Gundara JS; Glover A; Serpell J; Sidhu SB
    Oncologist; 2014 Nov; 19(11):1141-7. PubMed ID: 25323484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
    Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
    Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance.
    Lan X; Sun W; Zhang P; He L; Dong W; Wang Z; Liu S; Zhang H
    Tumour Biol; 2016 May; 37(5):6117-23. PubMed ID: 26611646
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
    Kim Y; Kim MH; Jeon S; Kim J; Kim C; Bae JS; Jung CK
    PLoS One; 2017; 12(3):e0174737. PubMed ID: 28358874
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer.
    Lee YS; Lim YS; Lee JC; Wang SG; Park HY; Kim SY; Lee BJ
    Oral Oncol; 2015 Jan; 51(1):77-83. PubMed ID: 25456009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters.
    Todorović L; Stanojević B; Mandušić V; Petrović N; Živaljević V; Paunović I; Diklić A; Saenko V; Yamashita S
    Med Oncol; 2018 Jan; 35(2):17. PubMed ID: 29340905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The stress-activated protein kinase pathway and the expression of stanniocalcin-1 are regulated by miR-146b-5p in papillary thyroid carcinogenesis.
    Al-Abdallah A; Jahanbani I; Mehdawi H; Ali RH; Al-Brahim N; Mojiminiyi O
    Cancer Biol Ther; 2020 May; 21(5):412-423. PubMed ID: 32037949
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.
    Sondermann A; Andreghetto FM; Moulatlet AC; da Silva Victor E; de Castro MG; Nunes FD; Brandão LG; Severino P
    Clin Exp Metastasis; 2015 Aug; 32(6):521-30. PubMed ID: 26007293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.
    Czarniecka A; Kowal M; Rusinek D; Krajewska J; Jarzab M; Stobiecka E; Chmielik E; Zembala-Nozynska E; Poltorak S; Sacher A; Maciejewski A; Zebracka-Gala J; Lange D; Oczko-Wojciechowska M; Handkiewicz-Junak D; Jarzab B
    PLoS One; 2015; 10(7):e0132821. PubMed ID: 26177218
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The miR-146b-3p/PAX8/NIS Regulatory Circuit Modulates the Differentiation Phenotype and Function of Thyroid Cells during Carcinogenesis.
    Riesco-Eizaguirre G; Wert-Lamas L; Perales-Patón J; Sastre-Perona A; Fernández LP; Santisteban P
    Cancer Res; 2015 Oct; 75(19):4119-30. PubMed ID: 26282166
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
    Xing M
    Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma.
    Zhang Y; Xu D; Pan J; Yang Z; Chen M; Han J; Zhang S; Sun L; Qiao H
    Oncol Lett; 2017 Jun; 13(6):4252-4266. PubMed ID: 28599426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.